Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U01 (ssCART-19) in Relapsed or Refractory B-cell Lymphoma
NCT07093073Phase 1Recruiting
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ssCART-19 in B cell lymphoma, sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. Primary endpoints: Adverse Events at 28 days, Objective Response Rate at 2 years and 3 more. Started Jan 2025; status: recruiting.
02
Drugs
ssCART-19
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT07093073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07093073.